Bhavya Bakshi, Sandeep Yerraguntla, Carmel Armon, Paul Barkhaus, Tulio Bertorini, Robert Bowser, Sarah Breevoort, Mark Bromberg, Andrew Brown, Gregory T Carter, Vincent Chang, Jesse Crayle, Timothy Fullam, Maxwell Greene, Terry Heiman-Patterson, Carlayne Jackson, Sartaj Jhooty, Elise Mallon, Javier Mascias Cadavid, Christopher J Mcdermott, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Yuyao Sun, Olivia Wang, Paul Wicks, Martina Wiedau, Richard Bedlack
{"title":"ALSUntangled #77: Psilocybin.","authors":"Bhavya Bakshi, Sandeep Yerraguntla, Carmel Armon, Paul Barkhaus, Tulio Bertorini, Robert Bowser, Sarah Breevoort, Mark Bromberg, Andrew Brown, Gregory T Carter, Vincent Chang, Jesse Crayle, Timothy Fullam, Maxwell Greene, Terry Heiman-Patterson, Carlayne Jackson, Sartaj Jhooty, Elise Mallon, Javier Mascias Cadavid, Christopher J Mcdermott, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Yuyao Sun, Olivia Wang, Paul Wicks, Martina Wiedau, Richard Bedlack","doi":"10.1080/21678421.2024.2441274","DOIUrl":null,"url":null,"abstract":"<p><p>ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation. Currently, there are no pre-clinical ALS models, case reports, or trials for psilocybin and ALS in the context of disease modifying therapy. Depending on dosing, there can be a high risk of psychological side effects including hallucinations and physical harm. Based on the above information, we do not currently support the use of psilocybin as a means to slow ALS progression.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":" ","pages":"385-388"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2441274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/22 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation. Currently, there are no pre-clinical ALS models, case reports, or trials for psilocybin and ALS in the context of disease modifying therapy. Depending on dosing, there can be a high risk of psychological side effects including hallucinations and physical harm. Based on the above information, we do not currently support the use of psilocybin as a means to slow ALS progression.